Showing 1141-1150 of 9130 results for "".
Tips for Success with Fillers
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/tips-for-success-with-fillers/20149/Heidi Waldorf, MD offers tips for getting the best results possible with fillers. From how to evaluate what patients need to considering shapes and proportions, she offers hands-on advice to help achieve optimal outcomes. Plus, she discusses the importance of managing patient expectations.Identifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and inDermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eDermWireTV: Cutera, Galderma Acne Treatments; Alma's TED; Diversity Initiatives
https://practicaldermatology.com/topics/practice-management/dermwiretv-cutera-galderma-acne-treatments-almas-ted-diversity-initiatives/20084/There are two new options for treating acne. Cutera introduces the AviClear acne device; Galderma launches Twyneo Cream. Joshua Zeichner, MD weighs in. Lady Dy, MD discusses Alma’s TED device, a non-invasive, non-traumatic option to address hair loss. New initiatives announced at or in conjunction wEBD Insights
https://practicaldermatology.com/conferences/maui-derm-2022/ebd-insights/20049/There are a number of new and reliable energy-based devices available. Michael H. Gold, MD discusses tried-and-true technologies as well as new and innovative devices that offer efficacious options on the market for a variety of dermatologic needs.DermWireTV: Updates from ASDS: EBDs, Injectables, Scars, DEI
https://practicaldermatology.com/topics/practice-management/dermwiretv-updates-from-asds-ebds-injectables-scars-dei/20029/The annual meeting of the American Society for Dermatology Surgery (ASDS) brings together top dermatologists to share their expertise. This year’s virtual meeting offered a look at a range of new and emerging treatments and some updates on existing options, including insights from Jeanine B. Downie,Managing Advanced Skin Cancers
https://practicaldermatology.com/conferences/aad-2021/managing-advanced-skin-cancers/19920/Treatment of advanced NMSC can be a challenge, but therapeutic options continue to expand. Todd Schlesinger, MD discusses real-world use of hedgehog inhibitors—including modified regimens and adjuvant use—and PD-1 inhibitors for advanced disease.DermWireTV: Pulse's CellFX, Soliton's RAP Technology, Belotero Balance (+), Restylane Defyne, Eczema Costs
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pulses-cellfx-solitons-rap-technology-belotero-balance-restylane-defyne-eczema-costs/19899/The FDA has cleared Pulse Biosciences’ CellFX system, and a commercial rollout will begin soon. There’s another new option for treatment for legs with FDA clearance of Soliton’s Rapid Acoustic Pulse technology for cellulite. For eight percent of Americans with atopic dermatitis, annual out of pocketDermWireTV: Cassiopeia Winlevi; Psoriasis Guidelines; Cyndi Lauper's PsO in the Know; Sarah Michelle Gellar's CoolSculpting
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cassiopeia-winlevi-psoriasis-guidelines-cyndi-laupers-pso-in-the-know-sarah-michelle-gellars-coolsculpting/19852/The FDA has approved Winlevi (Clascoterone cream 1%) from Cassiopea for the treatment of acne in patients 12 years and older.New Guidelines of care for the Management of Psoriasis with Systemic Nonbiologic Therapies, jointly issued by the American Academy of Dermatology and the National Psoriasis FoTreating Moderate to Severe Psoriasis: Weighing the Treatment Options
https://practicaldermatology.com/topics/psoriasis/-treating-moderate-to-severe-psoriasis-weighing-the-treatment-options/18375/In part 2 of her interview with DermTube Journal Club host Joshua Zeichner, MD, Erin Boh, MD reviews new biologics that provide patients with moderate to severe psoriasis improved treatment options. She discusses their efficacy and safety and offers tips for finding the right one for each patient ba